Premium
O1‐06‐01: Central BACE1 inhibition by LY2886721 produces opposing effects on APP processing as reflected by cerebrospinal fluid sAPP‐alpha and sAPP‐beta
Author(s) -
Willis Brian,
Martenyi Ferenc,
Dean Robert,
Lowe Stephen,
Nakano Masako,
Monk Scott,
Gonzales Celedon,
Mergott Dustin,
Daugherty Leslie,
Citron Martin,
May Patrick
Publication year - 2012
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2012.05.233
Subject(s) - chemistry , cerebrospinal fluid , medicine , endocrinology , pharmacodynamics , pharmacology , placebo , pharmacokinetics , alpha (finance) , pathology , surgery , alternative medicine , construct validity , patient satisfaction
O1-06-01 CENTRAL BACE1 INHIBITION BY LY2886721 PRODUCES OPPOSING EFFECTS ON APP PROCESSING AS REFLECTED BY CEREBROSPINAL FLUID SAPP-ALPHA AND SAPP-BETA Brian Willis, Ferenc Martenyi, Robert Dean, Stephen Lowe, Masako Nakano, Scott Monk, Celedon Gonzales, Dustin Mergott, Leslie Daugherty, Martin Citron, Patrick May, Eli Lilly and Co., Indianapolis, Indiana, United States; Lilly-NUS Centre for Clinical Pharmacology, Singapore, Singapore; 3 Eli Lilly Japan, K.K., Kobe, Japan.